コンテンツにジャンプ
先端医療開発センター

トップページ > グループ紹介 > 免疫トランスレーショナルリサーチ分野(柏) > 業績

業績

2018年

  1. Shitara K, and Nishikawa H.: Regulatory T cells: a potential target in cancer immunotherapy. Ann N Y Acad Sci. 2018 Apr;1417(1):104-115.
  2. Takeuchi Y, Tanemura A, Tada Y, Katayama I, Kumanogoh A, and Nishikawa H.: Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. Int Immunol. 2018 Feb 3;30(1):13-22.
  3. Shitaoka K, Hamana H, Kishi H, Hayakawa Y, Kobayashi E, Sukegawa K, Piao X, Lyu F, Nagata T, Sugiyama D, Nishikawa H, Tanemura A, Katayama I, Murahashi M, Takamatsu Y, Tani K, Ozawa T, and Muraguchi A.: Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis. Cancer Immunol Res. 2018 Apr;6(4):378-388.
  4. Ueda T, Aokage K, Nishikawa H, Neri S, Nakamura H, Sugano M, Tane K, Miyoshi T, Kojima M, Fujii S, Kuwata T, Ochiai A, Kusumoto M, Suzuki K, Tsuboi M, and Ishii G.: Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. J Cancer Res Clin Oncol. 2018 May;144(5):835-844.
  5. Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, and Kuwata T.: Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.: Gastric Cancer. 2018 Jun 1. doi: 10.1007/s10120-018-0843-9. [Epub ahead of print]

 

2017年

  1.  Nagase H, Takeoka T, Urakawa S, Morimoto-Okazawa A, Kawashima A, Iwahori K, Takiguchi S, Nishikawa H, Sato E, Sakaguchi S, Mori M, Doki Y, Wada H. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017 Feb 1;140(3):686-695

  2. Hamano Y, Kida H, Ihara S, Murakami A, Yanagawa M, Ueda K, Honda O, Tripathi LP, Arai T, Hirose M, Hamasaki T, Yano Y, Kimura T, Kato Y, Takamatsu H, Otsuka T, Minami T, Hirata H, Inoue K, Nagatomo I, Takeda Y, Mori M, Nishikawa H, Mizuguchi K, Kijima T, Kitaichi M, Tomiyama N, Inoue Y, Kumanogoh A. Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. Sci Rep. 2017 Feb 23;7:43201.

  3. Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H. NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC. J Immunother. 2017 Mar 23. doi: 10.1097/CJI.0000000000000162. [Epub ahead of print]

  4. Enokida T, Nishikawa H.: Regulatory T cells, as a target in anticancer immunotherapy.Immunotherapy. 2017 Jun;9(8):623-627. doi: 10.2217/imt-2017-0057. 査読有(Corresponding Author)

  5. Doki N, Suyama M, Sasajima S, Ota J, Igarashi A, Mimura I, Morita H, Fujioka Y, Sugiyama D, Nishikawa H, Shimazu Y, Suda W, Takeshita K, Atarashi K, Hattori M, Sato E, Watakabe-Inamoto K, Yoshioka K, Najima Y, Kobayashi T, Kakihana K, Takahashi N, Sakamaki H, Honda K, Ohashi K.: Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2017 Sep;96(9):1517-1523. doi: 10.1007/s00277-017-3069-8. Epub 2017 Jul 21.

  6. Togashi Y, Nishikawa H.: Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. Curr Top Microbiol Immunol. 2017 Sep 7. doi: 10.1007/82_2017_58.

  7.  Enokida T, Nishikawa H.: Regulatory T cells, as a target in anticancer immunotherapy. Immunotherapy. 9(8):623-627 2017.

  8. Nishiwaki S, Sugiura I, Miyata Y, Saito S, Sawa M, Nishida T, Miyamura K, Kuwatsuka Y, Kohno A, Yuge M, Kasai M, Iida H, Kurahashi S, Osaki M, Goto T, Terakura S, Murata M, Nishikawa H and Kiyoi H.: Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study). Medicine Dec;96(52):e9568 2017.

  9. Togashi Y, Nishikawa H.: Suppression from beyond the grave. Nat Immunol. 18(12):1285-1286 2017.

  10. Takeuchi Y, Tanemura A, Tada Y, Katayama I, Kumanogoh A, Nishikawa H.: Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. Int Immunol. 2017 Dec 23. (Corresponding Author).

     

2016年

  1. Shimazu Y, Hishizawa M, Hamaguchi M, Nagai Y, Sugino N, Fujii S, Kawahara M, Kadowaki N, Nishikawa H, Sakaguchi S, Takaori-Kondo A. Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia; Cancer Immunol Res. 2016 Feb;4(2):136-45.

  2.  Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T. Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.; Cancer Sci. 2016 Feb;107(2):189-202.

  3.  Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016 Jun;22(6):679-84 (Corresponding Author).

  4.  Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016 Aug;28(8):401-9 (Corresponding Author).

  5.  Ureshino H, Shindo T, Nishikawa H, Watanabe N, Watanabe E, Satoh N, Kitaura K, Kitamura H, Doi K, Nagase K, Kimura H, Samukawa M, Kusunoki S, Miyahara M, Shin-I T, Suzuki R, Sakaguchi S, Kimura S. Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia. Cancer Immunol Res. 2016 Aug;4(8):644-9

  6. Kakihana K, Fujioka Y, Suda W, Najima Y, Kuwata G, Sasajima S, Mimura I, Morita H, Sugiyama D, Nishikawa H, Hattori M, Hino Y, Ikegawa S, Yamamoto K, Toya T, Doki N, Koizumi K, Honda K, Ohashi K. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood. 2016 Oct 20;128(16):2083-2088

  7. Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T.: Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. Cancer Sci. 107(2):189-202 2016. doi: 10.1111/cas.12857.

  8. Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y , Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y and Sakaguchi S.: Two FOXP3+CD4+ T-cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 22(6):679-684 2016 doi: 10.1038/nm.4086. (Corresponding Author).

  9. Fujioka Y, Nishikawa H.: Basics of cancer immunotherapy. Rinsho Ketsueki. 2016;57(11):2346-2354

  10. Haseda F, Imagawa A, Nishikawa H, Mitsui S, Tsutsumi C, Fujisawa R, Sano H, Murase-Mishiba Y, Terasaki J, Sakaguchi S, Hanafusa T. Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. PLoS One. 2016 Aug 11;11(8):e0160576

  11. Okubo K, Wada H, Tanaka A, Eguchi H, Hamaguchi M, Tomokuni A, Tomimaru Y, Asaoka T, Hama N, Kawamoto K, Kobayashi S, Marubashi S, Nagano H, Sakaguchi N, Nishikawa H, Doki Y, Mori M, Sakaguchi S. Identification of Novel and Noninvasive Biomarkers of Acute Cellular Rejection After Liver Transplantation by Protein Microarray. Transplant Direct. 2016 Nov 18;2(12):e118.

     

2015年

  1. Nishikawa H. Overview: New Modality for Cancer Treatment. Oncology. Nov;8 9 Suppl 1:33-35 2015.
  2. Kurose K, Ohue Y, Wada H, Iida S, Takashi Ishida T, Kojima T Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E.; Phase Ia study of FoxP3+CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res. 21(19):4327-4336 2015.
  3. Adeegbe DO, Nishikawa H.; Regulatory T cells in cancer; can they be controlled? Immunotherapy. 7(8):843-846 2015 (Corresponding Author). 4. Miyara M, Chader D, Sage E, Sugiyama D, Nishikawa H, Bouvry D, Claër L, Hingorani R, Balderas R, Rohrer J, Warner N, Chapelier A, Valeyre D, Kannagi R, Sakaguchi S, Amoura Z, Gorochov G.; Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans. Proc. Natl. Acad Sci USA. 112(23):7225-7230 2015.
  4. Miyara
    M, Chader D, Sage E, Sugiyama D, Nishikawa H, Bouvry D, Claër L,
    Hingorani R, Balderas R, Rohrer J, Warner N, Chapelier A, Valeyre D, Kannagi R,Sakaguchi S, Amoura Z, Gorochov G.; Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3highregulatory T cells in humans. Proc. Natl. Acad Sci USA. 112(23):7225-7230 2015.